Health + Wellness

WHO Grants Emergency Approval For India’s Covaxin Jab

File photo of WHO signage.

The World Health Organization said Wednesday it had issued an emergency use listing for Covaxin, a vaccine against Covid-19 produced by India’s Bharat Biotech.

Found to have 78 percent efficacy after two doses spread over four weeks, the vaccine “is extremely suitable for low- and middle-income countries due to easy storage requirements,” the UN body said in a statement.

Covaxin is the first vaccine completely developed and manufactured in India to receive WHO approval.

READ ALSO: COP26: US Pledges To ‘Sharply’ Reduce Methane Emissions

Based on inactivated coronavirus antigens, it becomes the eighth vaccine against Covid-19 on the WHO’s list, including others from Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinopharm, and Sinovac.

WHO emergency approval, which includes an assessment of clinical trial data, can speed up international recognition of vaccines.

It also allows their use by fellow UN agencies and the global Covax initiative, set up to immunise people in the world’s least-well-off countries.

Related posts

Biden Opens Winter Battle Against COVID-19 Amid Omicron Concerns


Nigeria Records 344 New COVID-19 Cases


Dr. Tererai Trent: Rising From The Ashes To A Life That is Greater


Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More